Joyzyme Group Limited, operating under the abbreviated name HUAKANG BIOMED, has announced that its Board of Directors will convene on 28 August 2026. The agenda includes:

1. Approval of the unaudited condensed consolidated interim results for the six months ended 30 June 2026. 2. Consideration of an interim dividend distribution. 3. Discussion of other routine corporate matters.

The notice, released on 18 August 2026, confirms that the Board currently comprises four Executive Directors (Zhang Yujing, Zhou Xunyong, Zhang Chunguang and Poon Lai Yin Michael), one Non-executive Director (Bu Su) and three Independent Non-executive Directors (Chow Kwok Fai Joseph, Wang Yachun and Tsui Wing Tak).

The company affirms that the information disclosed is accurate and complete in all material respects, in adherence to the GEM Listing Rules of the Hong Kong Stock Exchange. The announcement will remain available on both the HKEX news website and the company’s corporate site for at least seven days from publication.